Download "Long acting HIV drugs to be developed

Long acting HIV drugs to be developed - University of Liverpool News - University of Liverpool
UNIVERSITY HOME
WELCOME: 中文 ‫ عربي‬ESPAÑOL
SITE A-TO-Z
LOGIN: STAFF
search
STUDENTS
NEWS
TUESDAY, 23
HEALTH
SEPTEMBER
| SCIENCE & TECHNOLOGY | CULTURE & SOCIETY
University of Liverpool > News > Long acting HIV drugs to be developed
PUBLISHED: SEPTEMBER 10, 2014
LEAVE A COMMENT | SHARE
CATEGORIES
Long acting HIV drugs to be
developed
HIV drugs which only need to be
taken once a month are to be
developed at the University of
Liverpool in a bid to overcome the
problem of ‘pill fatigue’.
Currently it is not uncommon for
people to miss doses of the
antiretroviral drugs that are used to treat HIV, due to the need for patients
to take them daily for the rest of their lives – an issue known as pill
fatigue.
University News
Expert opinion
Features
Film/Audio
The Liverpool View
Staff News
FOR MEDIA
Press Office Contacts
Press release archive
Expert directory
LATEST NEWS
To help address the problem, scientists based at the University of
Liverpool and Johns Hopkins University, USA are developing injections
that provide therapeutic exposure to the drugs for at least a month and
may replace daily tablets in some patients.
Emerging field
The injections will contain nanoparticles of the drug – approximately a
millionth of the size of a basketball. Nanomedicines are an emerging
field in pharmaceuticals which are designed by scientists to have specific
properties – this can involve making the medicines more targeted to
areas within the body such as diseased cells, or enable the drug to
remain in the body for a longer period of time.
A recent patient survey by one of the project collaborators from Johns
Hopkins indicated that almost 85% of patients would probably or
definitely try a once monthly nanoformulated antiretroviral drug.
http://news.liv.ac.uk/2014/09/10/long-acting-hiv-drugs-to-be-developed/[9/23/2014 10:15:46 AM]
Veterinary Scientist to
participate in tonight’s live
broadcast of `Dogs: Their
Secret Lives’
Construction begins on centre
dedicated to children’s health
University maintains position in
2015 University Guide
Multi-agency emergency
response exercise evaluated by
University
`Urban Forest’ photography
exhibition opens at School of
Architecture
All recent news
Long acting HIV drugs to be developed - University of Liverpool News - University of Liverpool
Pharmacologist, Professor Andrew Owen is leading the study in
Liverpool. He said: “The ability to administer drugs just once monthly is
an extremely exciting prospect for HIV therapy.
It is hoped that by studying
the critical mechanisms
for the ‘slow release’ in
HIV therapy, possibilities
for medicines in other
infectious diseases can be
opened up
“For orally delivered medicines,
much of the drug is often not
effectively absorbed into the body
and we therefore hope to be able
to lower the overall dose of drug
required. As such, the strategy
may also have benefits in
resource-limited settings by
reducing costs and supply chain
issues.”
NEWS FILTER
POPULAR MOST COMMENTED TAGS
POPULAR POSTS
Sorry. No data so far.
SOCIAL MEDIA
LATEST FROM
Medicinal chemist, Dr Caren Freel
Meyers is leading the study in
Baltimore along with leading HIV clinician, Dr Charles Flexner. She said:
“The multidisciplinary nature of the project will enable us to rapidly
progress new medicines, capitalizing on the synergistic strengths of the
teams at Johns Hopkins University and University of Liverpool.”
Dr Charles Flexner, Professor of Medicine and Deputy Director of the
Institute for Clinical and Translational Research at Johns Hopkins said:
“The University of Liverpool is one of the world’s premier institutions
working in nanomedicine, and we are thrilled to be able to develop this
collaboration between our two institutions.”
@LIVUNINEWS
We're working with
@AlderHeyCharity on a facility
to develop safer and more
effective medicines for children
t.co/VIndIK0gUM
FOLLOW
@LIVUNINEWS
ON
TWITTER.
facebook
New versions
The researchers will produce new versions of existing and commonly
used drugs. The most promising candidates will move forward for trials
and further testing. The research in Liverpool will utilise state-of-the-art
nanoformulation technology developed and led by Professor Steve
Rannard in the Department of Chemistry.
He commented: “We are finding increasingly new ways to apply
technologies for drug nanoparticle production developed at Liverpool.
The multi-disciplinary nature of our approach means that we are
focussed on the formation and optimisation of candidates that have a
large potential for clinical application leading to patient benefits. I am
hugely pleased that we have the collaboration with the teams at Johns
Hopkins as this will greatly enhance the potential for success.”
Cutting-edge mathematical modelling techniques will also be employed,
under the supervision of Dr Marco Siccardi in the Department of
Molecular and Clinical Pharmacology, to simulate the distribution of the
novel medicines within the human body.
Simplified therapy
http://news.liv.ac.uk/2014/09/10/long-acting-hiv-drugs-to-be-developed/[9/23/2014 10:15:46 AM]
Like us on
Facebook
More Social Media
Long acting HIV drugs to be developed - University of Liverpool News - University of Liverpool
It is also hoped that by studying the critical mechanisms for the ‘slow
release’ in HIV therapy, possibilities for medicines in other infectious
diseases can be opened up, in a similar way to those that have been
successful in schizophrenia and contraception.
The University is already working on nanotechnology-enabled medicines
for infection and cancer and the British Society of Nanomedicine was
launched from Liverpool.
Professor Owen, from the University’s Department of Molecular and
Clinical Pharmacology added: “Missing doses can place a selective
pressure in favour of development of resistance; any strategy that
simplifies therapy can have a major impact on treatment outcome.”
The project is funded by the US National Institutes of Health, Johns
Hopkins University and the University of Liverpool. It will last for four
years.
Find out more about about studying at Liverpool, by visiting the
University’s Study pages.
FURTHER READING
Nano-sized drug particles
to expand HIV treatment
further
CATEGORY
TAGS
Press Release
Department of Chemistry,
Department of Molecular and
Clinical Pharmacology, Dr Marco
Siccardi, Faculty of Health and Life
Sciences, Faculty of Science and
Engineering, Health, HIV, Institute
of Translational Medicine,
nanomedicine, Professor Andrew
Owen, Professor Steve Rannard,
School of Physical Sciences,
Science and Technology
LEAVE A COMMENT
You must be logged in to post a comment.
http://news.liv.ac.uk/2014/09/10/long-acting-hiv-drugs-to-be-developed/[9/23/2014 10:15:46 AM]
Long acting HIV drugs to be developed - University of Liverpool News - University of Liverpool
ARTICLES
RESOURCES
BY CATEGORY
BY MONTH
Expert opinion
September 2014
Features
August 2014
Film/Audio
July 2014
The Liverpool
View
June 2014
Social Media
May 2014
UNIVERSITY
NEWSLETTER
SUBSCRIBE TODAY
Email address*:
Sign up
Staff News
University of Liverpool,
L69 7ZX, UK
Email:[email protected]
© UNIVERSITY OF LIVERPOOL - A MEMBER OF THE RUSSELL
GROUP
http://news.liv.ac.uk/2014/09/10/long-acting-hiv-drugs-to-be-developed/[9/23/2014 10:15:46 AM]
MAP TERMS AND CONDITIONS ACCESSIBILITY